A phase I openlabel study to evaluate the effect of olaratumab on the pharmacokinetics (PK) of doxorubicin (Dox) in patients with advanced soft tissue sarcoma (STS)

Category Primary study
JournalCancer Research
Year 2016
This article has no abstract
Epistemonikos ID: a73f791c942dc3bfcda93dff8e7276f7d1b8198d
First added on: Feb 08, 2025